6533b7d7fe1ef96bd1268fc6
RESEARCH PRODUCT
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.
Bárbara Soria-juanNatalia EscacenaVivian Capilla-gonzálezYolanda AguileraLucía LlanosJuan R. TejedoJuan R. TejedoFrancisco J. BedoyaFrancisco J. BedoyaVerónica JuanAntonio De La CuestaRafael Ruiz-salmerónEnrique AndreuLukas GrochowiczFelipe PrósperFermín Sánchez-guijoFrancisco S. LozanoManuel MirallesLourdes Del Río-soláGregorio CastellanosJosé M. MoraledaRobert SacksteinMariano García-arranzDamián García-olmoFranz MartínFranz MartínAbdelkrim HmadchaAbdelkrim HmadchaBernat SoriaBernat SoriaBernat SoriaCollaborative Working Group “Noma Project Team”subject
0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem celldescription
The Collaborative Working Group “Noma Project Team”.
year | journal | country | edition | language |
---|---|---|---|---|
2019-06-01 |